Pharmaceutical

Janssen seeks EMA approval of RYBREVANT for NSCLC

Janssen has filed a Type II extension of indication application with the EMA seeking approval for Rybrevant for NSCLC.

Feb 10, 2024 - 18:00
Janssen seeks EMA approval of RYBREVANT for NSCLC
Janssen has filed a Type II extension of indication application with the EMA seeking approval for Rybrevant for NSCLC.
Read the original article

Tags:

Previous Article

Pharma and biotech concerned about the stability of large CROs, survey finds

Next Article

Boehringer and CBmed partner to develop cancer therapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

PXS-4728 by Syntara for Sleep Disorders: Likelihood of ...

Jan 25, 2024

STAT+: FDA warns of security vulnerability in Illumina’s DNA sequencing machines

STAT+: FDA warns of security vulnerability in Illumina’...

Apr 27, 2023

STAT+: Pharmalittle: Pfizer and Novo disclose upbeat data on oral weight loss drugs; PBM trade group blasts House committee over hearing

STAT+: Pharmalittle: Pfizer and Novo disclose upbeat da...

May 23, 2023